FOLH1 and prostate cancer: Although it is not possible to easily distinguish prostate cancer lung metastases from inflammatory conditions and primary lung cancers, PSMA overexpression in LC could expand the diagnostic applications of PSMA-based PET in the clinic (217, 219, 220).